The effect of bariatric surgery on glycemic control of diabetic patients has been extensively studied. Diabetes resolution after bariatric procedures is reported to be as high as 85%. The degree of hyperglycemia improved in most cases shortly after surgery. Yet, there is a relative paucity of data regarding the metabolic outcomes of bariatric operations in Israel. The aim of this study was to examine the early effects of surgery on weight loss as well as glycemic control parameters in one medical center in Israel..
Cortisol, but not ACTH/CRH, increases circulating ghrelin in man
Introduction: We have recently explored the involvement of ghrelin in the eating response to stress in humans and found that ghrelin levels increased in parallel to cortisol after a standardized psychological stress. To further elucidate this interaction, we examined the ghrelin response to pharmacological manipulation of the HPA axis.
Patients/ Methods: Following approval from the local Ethical Committee, six lean, healthy male volunteers were examined on two occasions. Blood samples were collected every 30 minutes for two sequential periods of two hours. Initially, a baseline period was followed by intravenous injection of ACTH 250 μg. Subsequently, metyrapone (2-3 g) was administered at midnight and in the following morning the initial 2-hour sampling was followed by intravenous injection of hydrocortisone 100 mg.
Results: Mean total ghrelin levels during the 2-hour period after metyrapone administration was significantly lower than during the period following ACTH administration (p=0.033). After ACTH stimulation, there was a positive correlation between total ghrelin and cortisol AUC (r=0.876, p = 0.021). Mean acylated ghrelin levels were lower during the post metyrapone sampling than in the baseline period (p=0.058). Furthermore, acylated ghrelin levels significantly increased after acute hydrocortisone administration (p = 0.032) and was positively correlated with the decrease in ACTH (R = 0.825, p = 0.043) and the increase in cortisol (r = 0.86, p=0.06). There was a highly positive correlation between total and acylated ghrelin levels during all phases of the study (r=0.96, p=0.002).
Conclusions:
In conclusion, increased cortisol levels secondary to ACTH stimulation or hydrocortisone administration is associated with increments in plasma ghrelin levels, whereas central stimulation of the HPA axis by blocking cortisol synthesis with metyrapone is associated with decreased plasma ghrelin levels. Collectively, this suggests that stress-induced elevations in ghrelin levels may be secondary to the rise in peripheral cortisol, independent of central elevation of ACTH and possibly CRH levels. Introduction: Inherited hypothyroidism occurs in approximately 1 of 20,000 live births. We recently reported a high prevalence of mutations of the thyroperoxidase (TPO) and TSH receptor (TSHR) genes in consanguineous communities of Northern Israel. The aim of the present study was to determine the genetic background of an extended family with familial occurrence of congenital hypothyroidism (CH) and high rate of hyperthyrotropinemia.
Patients/ Methods: Thirty members belonging to extended kindred of an ArabMuslim origin, two of whom with CH were enrolled. TSHR and TPO gene mutations were detected by sequencing.
Results: Three novel nucleotide substitutions in the extracellular region of the TSHR were identified in the same allele, two of which produced amino acid substitutions (Q90P and P264S). As one of the 2 subjects with CH had no TSHR gene mutation, other gene defects were sought. Two TPO gene mutations (G493S and R540X), which we previously described in the same population, were identified in different alleles. Thirteen individuals were heretozygous for the TSHR mutation, 9 of which were also heterozygous for one of the two TPO gene mutations. Of the 17 individuals heterozygous for one of the two TPO gene mutations, 4 had normal TSHR alleles. Of the 2 individuals with CH, one was homozygous for the TSHR gene mutation and one was compound heterozygous for the TPO mutations. Another homozygote for the TSHR mutation was born prior to the institution of neonatal screening. Genotypephenotype correlation based on TSH concentration revealed no differences between heterozygotes for either TPO mutations (N=8) and WT (N=6). In contrast, heterozygotes for the TSHR mutation had significantly higher TSH compared to WT family members (7.1±0.3 vs. 2.3±0.5). TSH values in the two homozygotes for the TSHR mutation were 31 and 58 mU/L, and both had low FT4 levels.
Mutations of TPO and TSHR genes were found to coexist in the same consanguineous kindred. Patients homozygous for the TSHR gene mutation and compound heterozygous for the TPO gene mutation presented with hypothyroidism. The mild hyperthyrotropinemia of heterozygotes with the TSHR gene mutation was not aggravated by the coexistence of a TPO defect in only one allele. Introduction: Differentiated thyroid cancer usually affects women of child-bearing age. During normal pregnancy, several factors may have a stimulatory effect on normal and nodular thyroid growth. The present study aimed to determine if pregnancy in thyroid-cancer survivors poses a risk of progression or recurrence of the disease
Impact of pregnancy on

Patients/ Methods:
A retrospective evaluation of consecutive women who were followed at a single Endocrine Institute for differentiated epithelial thyroid cancer and who had at least one pregnancy and delivery after receiving treatment for thyroid cancer between 1992 and 2009. The patients' medical records were reviewed for data including age at diagnosis, pathological cancer staging, number of operations, number and doses of radioactive iodine treatments the patient underwent, interval from diagnosis to pregnancy, thyroglobulin (Tg) levels and neck ultrasound findings before and after pregnancy, and thyroid stimulating hormone (TSH) levels during pregnancy. Tg levels and neck ultrasound findings were compared before and after pregnancy. Disease progression in pregnancy was defined as a significant increase in Tg level, a new imaging finding or enlargement of a known pre-pregnancy mass suggestive for thyroid cancer metastasis within a year after delivery. The demographic and diseaserelated characteristics and levels of TSH measured in pregnancy were correlated with disease progression during pregnancy using Pearson correlation analysis.
Results:
Sixty-three women met the study criteria. The mean time to the first delivery after completion of initial thyroid-cancer treatment was 5.16±3.76 years, the mean duration of follow-up after delivery was 4.66±3.75 years. Forty women had one and 23 women had more than one delivery, for a total of 90 births. Biochemical and/or imaging evidence of thyroid cancer progression during the first pregnancy after treatment was documented in 9 patients (14.2%). Three of them also showed disease progression during a second pregnancy. Another 3 patients showed no disease progression during the first pregnancy but did so during the second. TSH was measured 4.87±2.24 times during pregnancy and mean TSH level was 2.53±4.03 mIU/ml. There was no correlation of most of the indices evaluated with disease progression during pregnancy. A strong positive correlation with cancer progression during pregnancy was noted for persistence of thyroid cancer before pregnancy and total I-131 dose administered.
Conclusions:
Pregnancy does not cause thyroid cancer progression or recurrence in thyroid-cancer survivors who have no structural or biochemical evidence of disease persistence before pregnancy. However, in the presence of such evidence, disease progression may occur during pregnancy, yet not necessarily as a consequence of pregnancy. A non-suppressed TSH level during pregnancy does not stimulate disease progression in thyroid-cancer survivors and may be an acceptable therapeutic goal, especially in those with a history of miscarriages or preterm deliveries.
Introduction:
Although the treatment of Graves' thyrotoxicosis with radioactive iodine is generally perceived as clinically efficient, cost effective and safe, most radioiodine-treated patients become hypothyroid rapidly after radioiodine treatment and need life-long thyroxine replacement. Further, observational studies show that radioiodine therapy is linked to increased mortality due to cardio-and cerebrovascular disease. Here we evaluated the cardiometabolic outcome of radioiodine-treated (RI) vs. medically treated (Med) subjects with Grave's disease as assessed after ≥ 3 years of follow up.
Patients/ Methods:
All subjects were actively recruited to undergo complete physical examination and blood testing which included glucose, HBA1C, CRP, liver, kidney and thyroid function. Non-diabetic patients also underwent 75 gram oral glucose tolerance test. Arterial stiffness was evaluated using applanation tonometry and pulse wave analysis by different standard devices which assess distinct measures of arterial stiffness: pulse wave velocity (PWV), augmentation index, and large/small artery compliance (C1 and C2). Additionally, all subjects were referred for ambulatory blood pressure monitoring.
Results:
Sixty five RI-treated and 33 Med-treated patients with Graves' disease were included in the study. Mean age (53±12 vs. 48±13.6, p=NS), gender (M-28% vs. 21%, p=NS), duration of the disease (5.2 vs. 5.3 yrs, p=NS), and thyroid function tests (TSH: 2±1.4 vs. 1.6±1.1, p=NS) were similar in the RI and Med groups, respectively. Post-RI-therapy patients had higher BMI, waist circumference, systolic blood pressure, PWV, hs-CRP levels, higher prevalence of the metabolic syndrome and lower C2 than antithyroid drug-treated patients. After adjustment to age and gender RI-treated patients had higher BMI (27.4±5.7 vs. 24.3±3.6, p=0.03), hs-CRP levels (4.14±5.3 vs. 1.62±1.44, p=0.047), and higher prevalence of the metabolic syndrome (52.3 vs.15.6%, p=0.003).
Conclusions:
Radioiodine treated patients with Grave's disease gain more weight and have higher rate of the metabolic syndrome compared with medically treated subjects with this condition. The difference is seen despite normal and indistinguishable thyroid hormone levels with thyroxin treatment. We suggest that in the choice between these two major therapeutic modalities, physicians and patients should be aware of this emerging difference in outcome. Additionally, RI-treated patients should be carefully followed in an attempt to reduce the risk of weight gain and the metabolic syndrome.
